EGFR and Parkinson disease: Despite these many unresolved questions, the present study revealed the molecular basis for the recognition and mechanism of action of semagacestat and EGFR, suggesting that semamacestat may improve the pathology of AD and comorbid PD through EGFR, which may ultimately lead to potent therapeutics targeting AD and comorbid PD.